Our data, together with other published results, provide the ground for further studies of the underlying molecular mechanisms of cytoprotective and anti-inflammatory effects of PARP inhibitors, as well as the therapeutic potential of PARP inhibition to prevent or delay immune inflammatory diseases, including ovarian dysfunction, caused by endotoxemia. This evidence concerns the gene PARP1 and ovarian dysfunction.